Патогенетический подход к лечению ожирения и сахарного диабета 2 типа

1. Анциферов М.Б. Дорофеева Л.Г. Сибутрамин (Меридиа) в терапии ожирения у больных сахарным диабетом 2 типа. Медицина. Качество жизни 2006; 3(14): 1-4.

2. Г.А. Мельниченко, Т.И. Романцова. Ожирение: эпидемиология, классификация, патогенез, клиническая симптоматика и диагностика. «Ожирение» - Под ред. И.И. Дедова, Г.А. Мельниченко. М., «Московское информационное агентство», 2004: 16-43.

3. Панков Ю.А. Лептин в регуляции нейроэндокринной системы. Актуальные проблемы нейроэндокринологии. Материалы III Всероссийской научно-практической конференции. М., 2003; 27-38.

4. Романцова Т.И., Волкова Г.Е. Лептин и грелин: антагонизм и взаимодействие в регуляции энергетического обмена. Ожирение и метаболизм 2005; 2: 2-9.

5. Романцова Т.И., Дедов И.И., Кузнецов И.С. Эндоканнабиноидная система: структура и потенциальные возможности в регуляции массы тела. Ожирение и метаболизм 2006; 4 : 2-11.

6. Andersen J.W., Kendal C.W.C., Jenkins D.J.A. Importance of weight management in type 2 diabetes: review with meta - analysis of clinical studies. J Am Col Nutr 2003; 22 (5): 331-339.

7. Balkau B., Deanfield J.E., Despres J.-P. et al. International Day for Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease and diabetes mellitus in 168.000 primary care patients in 63 countries. Circulation 2007; 116: 1942-1957.

8. Barsh G.S., Schwartz M.W. Genetic approaches to studying energy balance: perception and integration. Nuture Reviews 2002; 3: 589-600.

9. Bernard C. Lecons de physiologie experimentale appliquees a la me dicine. 1854, Paris: Baillere et Fils.

10. Casanueva F.F. Neuroendocrinology of leptin and ghrelin. // Abstracts of 11th Meeting of the European Neuroendocrine Association. Napoli, 2004: P. 78.

11. Christian B., Kahn B. Leptin Signaling in the Central Nervous System and the Periphery Recent Progress in Hormone Research 2004; 59: 305-331.

12. Colditz G.A., Willett W., Rotnitzky A., Manson J. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.

13. Cone R.D. Anatomy and regulation of the central melanocortin system. Nature Neuroscience 2005; 8: 571-578.

14. Cummings D.E., Schwartz M.W. Melanocortins and body weight: a tale of two receptors. Nature Genetics, 2000; 26: 8-9.

15. D.M. Dinulescu D.M., Cone R.D. Agouti and Agouti-related Protein: Analogies and Contrasts. J Biol Chem 2000; 275(10): 6695 - 6698.

16. Diabetes Prevention Program Research Group: Reduction in the incidence of the type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2003; 346: 393-403.

17. Finer N., Bloom S.R., Frost G.S. et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000; 2: 105-112.

18. Franz M.J. The dilemma of weight loss in diabetes. Diabetes spectrum 2007; 20(3): 133-136.

19. Franz M.J. The evidence is in: lifestyle interventions can prevent diabetes. Am J Lifestyle Med 2007, 1 (2): 113-121.

20. Fujioka K., Seaton T.B., Rowe E. Et al., The Sibutramine / Diabetes Clinical Study Group: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2:175-187.

21. Gantz I., Fong T.M. The melanocortin system. Am J Physiol Endocrinol Metab 2003; 284: 468-474.

22. Goteel A., Karakose H., Ertorer E.D. et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 1957-1960.

23. Hansen D.L. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180-1186.

24. Heal D.J., Cheetham S.C. The pharmacology of sibutramine, the first serotonin and noradrenaline re-uptake inhibitor to be developed for the treatment of obesity. Lett Pharmacol 1997; 11 (Suppl.10): 3-8.

25. Heisler L.K., Cowley M.A., Tecott L.H. et al. Activation of central melanocortin pathways by fenfluramine. Science 2002; 297: 609-611.

26. Heisler L.K., Erin E., Jobst E.E., Sutton G.M. et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006; 51: 239-249.

27. Kalra S.P., Dube M.G., Pu S. et al. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68-100.

28. Kalra S.P., Bagnasco M., Otukonyong E.E. et al. Rhythmic, reciprocal ghrelin and leptin signaling: new insight of the development of obesity. // Regulatory peptides 2003; 111: 1-11.

29. Knowler W.C., Pettitt D., Savage P.J., Bennett P.H. Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidemiol 1981; 113: 144-56.

30. Lean M., Powrie J., Anderson A.S., Garthwaite P. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-233.

31. Lindstrоm J., Louheranta A., Mannelin M. et al. The Finnish Diabetes Prevention Study (DPS). Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-3236.

32. Mori H., Hanada R., Hanada T., Aki D. et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004; 10:739-743.

33. Neary N.M., Goldstone A.P., Bloom S.R. Appetite regulation: from the gut to the hypothalamus. Clin Endocrinol 2004; 60: 153-160.

34. Niswender K.D., Schwartz M.W. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol 2003; 24: 1-10.

35. Obici S., Feng Z., Karkanias G. et al. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 2002; 5: 566-572.

36. Obici S., Zhang B.B., Karkanias G., Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002; 8:1376-1382.

37. Okamoto H., Jun Nakae J., Kitamura T. et al. Transgenic rescue of insulin receptor-deficient mice J Clin Invest 2004; 114(2): 214-223.

38. Olinto M.T.A., Nacul L.C., Gigante D.P. Waist circumference as a determinant of hypertension and diabetes in Brasilian women: a population-based study. Public Health Nutrition 2003; 7 (5): 629-635.

39. Porte D., Baskin D.G., Schwartz M.W. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005; 54:1264-1276.

40. Porte D. Central Regulation of Energy Homeostasis. The Key Role of Insulin. Diabetes 2006; 55: 155-160.

41. Powell D.R. Obesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo. Obes Rev 2006; 7, 89-108.

42. Prodi E., Obici S. Minireview: the brain as a molecular target for diabetic therapy. Endocrinol 2003; 144: 1363-1364.

43. Redmon J.B., Raatz S.L., Reck K.P. et al. One - year outcome of a combination of weight loss therapies for subjects with type 2 diabetes. Diabetes Care 2003; 26: 51-61.

44. Schwartz M.W., Woods S.C., Porte D. et al. Central nervous system control of food intake. Nature 2000; 404: 661-671.

45. Schwartz M.W., Porte D. Diabetes, obesity, and the brain. Science 2005; 307: 375-379.

46. Schwartz M.W. Central nervous system regulation of food intake. Obesity 2006; 14: 1-8

47. Shi H., Tzameli I., Bjorbaek C., Flier J.S. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 2004; 279: 34733-34740.

48. Stanly S., Wynne K., McGowan B., Bloom S. Hormonal regulation of food intake. Physiol Rev 2005; 85: 1131-1158.

49. Tuomelihto J., Lindstrom J., Eriksson J.G. for the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes by changes in lifestyle among subjects with impared glucose tolerance. N Engl J Med 2001; 344: 1343-1350.

50. van Gaal L.F., Peiffer F.W. The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes 2001; 25 (Suppl 4): 24-28.

51. Vazquez G., Duval S., Jacobs D.R., Silventoin K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiologic Reviews 2007; 10: 1-14.

52. Vettor R., Serra R., Fabris R. et al. Effect of sibutramine on weight management and metabolic control in type 2 diabetes. A meta-analysis of clinical studies. Diabetes Care 2005; 28: 942-949.

53. Williamson D., Thompson T., Thun M. et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23:1499-1504.

54. Wilson B.D., Ollmann M.M., Kang L., et al. Structure and function of ASP, the human homolog of the mouse agouti gene. Hum Mol Genet 1995; 4: 223-230.

55. Wilson B.D., Bagnol D., Yang Y.-K. Biochemical and genetic studies of endogenous melanocortin receptor antagonists. In: Progress in obesity research. Ed. By Guy-Grand B., Ailhaud G. - London, 1999; 289-297.

56. Woods S.C., Benoit S.C., Clegg D.J. The Brain-Gut-Islet Connection. Diabetes 2006; 55(Suppl.2): 114-121.

57. Wynne K., Stanly S., McGowan D., Bloom S. Appetite control. J Endocrinol 2005; 184: 291-318.

58. Yang W., Kelly T., He J. Genetic Epidemiology of Obesity. Epidemiol Rev 2007: 1-13